source
- Boehringer presents phase 1b data on obrixtamig showing strong response rates in second-line small cell lung cancerBoehringer Ingelheim presented updated data from its DAREON-9 phase 1b trial at the ESMO Congress in Madrid, evaluating the DLL3xCD3 bispecific T-cell engager obrixtamig in combination with topotec…
- Telehealth platforms prescribe GLP-1 drugs off-label for addiction, raising safety concernsTelehealth companies have begun prescribing GLP-1 receptor agonists, originally approved for diabetes and obesity, to patients with alcohol, cocaine, methamphetamine or other substance use disorder…